44 p.El tumor ven?reo transmisible canino (TVTc) es una neoplasia ampliamente estudiada, y debido a su comportamiento biol?gico, presenta un grado significativo de contagio en la especie dom?stica Canis lupus familiaris L., principalmente en los individuos sin hogar. Esta enfermedad tumoral, ampliamente distribuida a nivel mundial, presenta m?ltiples mecanismos de dispersi?n (lamer, rascar o morder las partes afectadas), contribuyendo con los impactos a nivel cl?nico y epidemiol?gico. Dentro de los tratamientos cl?nicos convencionales se destaca la quimioterapia usando sulfato de vincristina, sin embargo, recientes estudios han reportado resistencia a este tratamiento, principalmente hacia el subtipo TVTc plasmoc?tico. La presente revisi?n aborda el uso de la ivermectina en el tratamiento del TVTc. Se analizaron tres casos cl?nicos para TVTc con morfolog?a plasmoc?tica diagnosticados mediante citolog?a y confirmados por histopatolog?a. Estos casos fueron tratados farmacol?gicamente combinando sulfato de vincristina (0,5 a 0,7 mg / m2 de ?rea de superficie corporal v?a intravenosa semanalmente) e ivermectina (0,5 mg / Kg v?a subcut?nea semanalmente), logrando la remisi?n completa con menos de 5 aplicaciones sin complicaciones cl?nicas.Canine transmissible venereal tumor (TVT) is a neoplasm widely studied and, because of its biological behavior, a significant contagion degree has been identified in Canis lupus familiaris L., mainly in homeless dogs. This worldwide tumoral disease shows multiple dispersal mechanisms (leaking, scratching, and biting the infected areas), contributing to the clinical and epidemiological impacts. Among conventional clinical treatments chemotherapy by using vincristine sulfate is the most prominent. However, recent studies have demonstrated tumoral resistance to this treatment, basically towards the TVT plasmacytic subtype. The present review addresses the use of ivermectin for TVT treatment. Three clinical cases, taken from a particular clinic and previously diagnosed through cytology and confirmed by histopathology, were analyzed. All the clinical cases were under pharmacological treatment by combining vincristine sulfate (0.5 to 0.7 mg / m2 of body surface area intravenously weekly) and ivermectin (0.5 mg / Kg subcutaneously weekly), achieving complete remission with less than 5 applications without clinical complications.